Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; KYNMOBI a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. The company's proprietary pipeline products include Anaphylm, an epinephrine sublingual film, which is in phase 3 clinical trial for the emergency treatment of allergic reactions, including anaphylaxis; and AQST-108, a topical gel that is in phase 2 clinical trial for the treatment of alopecia areata. In addition, it develops PharmFilm technology for patients suffering from certain central nervous system disorders; and Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.

Aquestive Therapeutics Inc.

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Aquestive Therapeutics (AQST – Research Report) and ...

Analysts’ Top Healthcare Picks: Aquestive Therapeutics (AQST), Skye Bioscience (SKYE)

Since the start of the month, the U.S. Food and Drug Administration (FDA) has made its decision on at least three drug applications filed by variou...

FDA Calendar: These Are the Remaining Drug Approvals Anticipated This Month

Traders will find all of the earnings, analyst ratings, and deals driving the stock market on Friday.


Morning News Wrap-Up: Friday’s Biggest Stock Market Stories!

Lake Street analyst Thomas Flaten maintained a Buy rating on Aquestive Therapeutics today and set a price target of $8.00. According to TipRanks, F...

Lake Street Reaffirms Their Buy Rating on Aquestive Therapeutics (AQST)

Aquestive Therapeutics stock was slammed by an FDA update for its Anaphylm New Drug Application.


Why Is Aquestive Therapeutics Stock (AQST) Down Today?

Aquestive Therapeutics ( ($AQST) ) just unveiled an update. On January 9, 2026, Aquestive Therapeutics announced that the U.S. Food and Drug Admini...

Current Quarter	$-0.13	Next Quarter	$-0.16
Current Year	$-0.64	Next Year	$-0.56
QoQ Growth	-23.1%	YoY Growth	+12.5%
3Y EPS CAGR	+34.9%	Target Price	$9.00
Consensus	Buy	Upside	+119.5%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	AQST	$4.10	0.00%	7.63M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	AQST	$4.10	0%	7.63M
3
4
5
6

AQST

AQST

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Aquestive Therapeutics Inc. Data in Excel

Get Aquestive Therapeutics Inc. Data in Excel